Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas

Abstract

Objective: To evaluate the prevalence of impulse control disorders (ICD) and psychiatric symptoms in patients with acromegaly receiving dopamine agonists (DA) in comparison with those with prolactinoma, nonfunctioning pituitary adenomas (NFA), and healthy controls (HC).